Home
/
TEVA PHARMACEUTICAL INDUSTRIES LTD
/
Financials
/
Quarterly
TEVA PHARMACEUTICAL INDUSTRIES LTD — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that TEVA PHARMACEUTICAL INDUSTRIES LTD filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$4.48B
Nov 5, 2025
Q2
2025
Jun 30, 2025
$4.18B
Jul 30, 2025
Q1
2025
Mar 31, 2025
$3.89B
May 7, 2025
Q3
2025
Sep 30, 2024
$4.33B
Nov 5, 2025
Q2
2025
Jun 30, 2024
$4.16B
Jul 30, 2025
Q1
2025
Mar 31, 2024
$3.82B
May 7, 2025
Q3
2024
Sep 30, 2023
$3.85B
Nov 6, 2024
Q2
2024
Jun 30, 2023
$3.88B
Jul 31, 2024
Q1
2024
Mar 31, 2023
$3.66B
May 8, 2024
Q3
2023
Sep 30, 2022
$3.60B
Nov 9, 2023
Q2
2023
Jun 30, 2022
$3.79B
Aug 2, 2023
Q1
2023
Mar 31, 2022
$3.66B
May 10, 2023
Q3
2022
Sep 30, 2021
$3.89B
Nov 3, 2022
Q2
2022
Jun 30, 2021
$3.91B
Jul 27, 2022
Q1
2022
Mar 31, 2021
$3.98B
May 3, 2022
Q3
2021
Sep 30, 2020
$3.98B
Oct 27, 2021
Q2
2021
Jun 30, 2020
$3.87B
Jul 28, 2021
Q1
2021
Mar 31, 2020
$4.36B
Apr 28, 2021
Q3
2020
Sep 30, 2019
$4.09B
Nov 5, 2020
Q2
2020
Jun 30, 2019
$4.18B
Aug 5, 2020
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$5.07B
May 3, 2018
Q4
2017
Dec 31, 2017
$5.46B
Feb 12, 2018
Q4
2017
Sep 30, 2017
$5.61B
Feb 12, 2018
Q4
2017
Jun 30, 2017
$5.72B
Feb 12, 2018
Q1
2018
Mar 31, 2017
$5.65B
May 3, 2018
Q4
2017
Mar 31, 2017
$5.65B
Feb 12, 2018
Q4
2017
Dec 31, 2016
$6.49B
Feb 12, 2018
Q4
2017
Sep 30, 2016
$5.56B
Feb 12, 2018
Q4
2017
Jun 30, 2016
$5.04B
Feb 12, 2018
Q4
2017
Mar 31, 2016
$4.81B
Feb 12, 2018
Q4
2017
Dec 31, 2015
$19.65B
Feb 12, 2018
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$433.00M
Nov 5, 2025
Q2
2025
Jun 30, 2025
$282.00M
Jul 30, 2025
Q1
2025
Mar 31, 2025
$214.00M
May 7, 2025
Q3
2025
Sep 30, 2024
($437.00M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($846.00M)
Jul 30, 2025
Q1
2025
Mar 31, 2024
($139.00M)
May 7, 2025
Q3
2024
Sep 30, 2023
$69.00M
Nov 6, 2024
Q2
2024
Jun 30, 2023
($872.00M)
Jul 31, 2024
Q1
2024
Mar 31, 2023
($220.00M)
May 8, 2024
Q3
2023
Sep 30, 2022
$56.00M
Nov 9, 2023
Q2
2023
Jun 30, 2022
($232.00M)
Aug 2, 2023
Q1
2023
Mar 31, 2022
($955.00M)
May 10, 2023
Q3
2022
Sep 30, 2021
$292.00M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$207.00M
Jul 27, 2022
Q1
2022
Mar 31, 2021
$77.00M
May 3, 2022
Q3
2021
Sep 30, 2020
($4.35B)
Oct 27, 2021
Q2
2021
Jun 30, 2020
$140.00M
Jul 28, 2021
Q1
2021
Mar 31, 2020
$69.00M
Apr 28, 2021
Q3
2020
Sep 30, 2019
($314.00M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($689.00M)
Aug 5, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$882.00M
Nov 5, 2025
Q2
2025
Jun 30, 2025
$455.00M
Jul 30, 2025
Q1
2025
Mar 31, 2025
$519.00M
May 7, 2025
Q3
2025
Sep 30, 2024
($51.00M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($5.00M)
Jul 30, 2025
Q1
2025
Mar 31, 2024
($218.00M)
May 7, 2025
Q3
2024
Sep 30, 2023
$344.00M
Nov 6, 2024
Q2
2024
Jun 30, 2023
($654.00M)
Jul 31, 2024
Q1
2024
Mar 31, 2023
($13.00M)
May 8, 2024
Q3
2023
Sep 30, 2022
$419.00M
Nov 9, 2023
Q2
2023
Jun 30, 2022
($949.00M)
Aug 2, 2023
Q1
2023
Mar 31, 2022
($713.00M)
May 10, 2023
Q3
2022
Sep 30, 2021
$623.00M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$582.00M
Jul 27, 2022
Q1
2022
Mar 31, 2021
$434.00M
May 3, 2022
Q3
2021
Sep 30, 2020
($4.34B)
Oct 27, 2021
Q2
2021
Jun 30, 2020
$173.00M
Jul 28, 2021
Q1
2021
Mar 31, 2020
$191.00M
Apr 28, 2021
Q3
2020
Sep 30, 2019
($81.00M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($644.00M)
Aug 5, 2020